Cancer Research UK has enlisted contract drugmaker Onyx Scientific to pitch in on some of its early research projects, handling development and manufacturing for clinical trials.
Drug developer Catalent is teaming up with biomarker outfit Minomic International to get a new prostate cancer treatment into the clinic, tapping its expertise in crafting targeted oncology treatments.
Swedish contract developer Recipharm is looking to expand its share of the European manufacturing market, trading $164.5 million for Italy's Corvette Pharmaceutical Services.
Contract drug developer AMRI posted a 15% boost in its quarterly revenue, using M&A and manufacturing demand to help wean it off royalty cash.
Repeated regulatory woes for SCM Pharma have left the U.K. contract manufacturer unable to afford its necessary upgrades, forcing Shire, its largest customer, to step in and take over.
Contract developer Almac has earmarked £54 million ($90 million) to expand in its native Northern Ireland, planning to add 348 jobs over 5 years.
GlaxoSmithKline has submitted its plans to whip its troubled Quebec flu vaccine plant into shape to Health Canada, and the regulator says the action outline is up to snuff.
Cubist Pharmaceuticals is recalling 100 lots of its banner antibiotic Cubicin after problems with a contract manufacturer, its third such issue in 12 months.
GlaxoSmithKline is in the process of reviewing regulatory results from a June inspection that found that 10 areas of its Ste. Foy, Quebec, vaccine manufacturing plant needed improvements. But in the meantime, Health Canada has imposed a condition on the facility's license, requiring notice before Glaxo resumes production of Fluviral and FluLaval Tetra.
Russia is striving to produce domestically 50% of the drugs sold in the country, and, to do so, it's encouraging global manufacturers to buy, build or rent facilities there.